drugset / Trial / NCT01487161

Study of FX006 in Patients With Osteoarthritis of the Knee

NCT01487161

Phase 2 Completed 229 enrolled Pacira Pharmaceuticals, Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study was to evaluate the safety, efficacy and pharmacokinetics of FX006 in patients with osteoarthritis of the knee.

Timeline

Start
2012-06
Primary completion
2013-04
Completion
2013-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator TCA IR Unknown 40 mg Other
Subject Tafamidis Unknown 10 mg Other
Subject Tafamidis Unknown 40 mg Other
Subject Tafamidis Unknown 60 mg Other

Indications